Las dificultades del aprendizaje autónomo en un contexto de ABP

Objectives: To identify the difficulties that the students have in a process of selflearning. To elaborate an inventory of the identified difficulties. To diagnose the causes of the difficulties and to point routes or possibilities of overcoming. To evaluate the impact of the difficulties in the end item. Empiric analysis data: 80 students of the two last years in law studies. Academic year 2006-2007. Faculty of Law of the University of Barcelona. Methodology: Ethnografic study. Results: For students who do not have previous experience in ABP the greater difficulty is the disorientation and the anguish that suffer because of the absence of an agenda. They exist difficulties of interaction with the tutors derived from the divergent conception and intelligence of meaning. Finally, difficulties derived from the influence of the surroundings (personal habits) and connected others with the learning styles of each student have been detected.Objetivos: Identificar las dificultades que experimentan los estudiantes en un proceso de aprendizaje autodirigido. Elaborar un inventario y una clasificación de las dificultades identificadas. Diagnosticar las causas de las dificultades y apuntar vías o posibilidades de superación. Evaluar el impacto de las dificultades en el producto final. Datos del análisis empírico: Participan en el estudio un total de 80 estudiantes de los dos últimos cursos de la licenciatura de Derecho. Curso académico 2006-2007. Facultad de Derecho de la Universidad de Barcelona. Metodología de trabajo: Estudio etnográfico. Resultados: Para los estudiantes que no tienen experiencia previa en ABP la mayor dificultad es la desorientación y la angustia que sufren ante la ausencia de un temario. Existen dificultades de interacción con los tutores derivadas de la divergente concepción e inteligencia de significados. Finalmente, se han detectado dificultades derivadas de la influencia del entorno (hábitos personales) y otras conectadas con los estilos de aprendizaje de cada estudiante

High-resolution hepatitis C virus subtyping using NS5B deep sequencing and phylogeny, an alternative to current methods

HepatitisCvirus(HCV)is classified into seven major genotypesand67 subtypes. Recent studies haveshownthat inHCVgenotype 1-infected patients, response rates to regimens containingdirect-acting antivirals(DAAs)are subtype dependent. Currently available genotypingmethods have limited subtyping accuracy.Wehave evaluated theperformanceof adeep-sequencing-basedHCVsubtyping assay, developed for the 454/GS-Junior platform, in comparisonwith thoseof two commercial assays (VersantHCVgenotype 2.0andAbbott Real-timeHCVGenotype II)andusingdirectNS5Bsequencing as a gold standard (direct sequencing), in 114 clinical specimenspreviously tested by first-generation hybridization assay (82 genotype 1and32 with uninterpretable results). Phylogenetic analysis of deep-sequencing reads matched subtype 1 callingbypopulation Sanger sequencing(69%1b,31%1a) in 81 specimensandidentified amixed-subtype infection (1b/3a/1a) in one sample. Similarly,amongthe 32previously indeterminate specimens, identical genotypeandsubtype results were obtained by directanddeep sequencing in all but four samples with dual infection. In contrast, both VersantHCVGenotype 2.0andAbbott Real-timeHCVGenotype II failed subtype 1 calling in 13 (16%) samples eachandwere unable to identify theHCVgenotype and/or subtype inmore than half of the nongenotype 1 samples.Weconcluded that deep sequencing ismore efficient forHCVsubtyping than currently available methodsandallows qualitative identificationofmixed infectionsandmay bemorehelpfulwith respect to informing treatment strategies withnewDAA-containing regimens across allHCVsubtypesThis study has been supported by CDTI (Centro para el Desarrollo Tecnológico Industrial), Spanish Ministry of Economics and Competitiveness (MINECO), IDI-20110115; MINECO projects SAF 2009-10403; and also by the Spanish Ministry of Health, Instituto de Salud Carlos III (FIS) projects PI10/01505, PI12/01893, and PI13/00456. CIBERehd is funded by the Instituto de Salud Carlos III, Madrid, Spain. Work at CBMSO was supported by grant MINECO-BFU2011-23604, FIPSE, and Fundación Ramón Areces. X. Forns received unrestricted grant support from Roche and has acted as advisor for MSD, Gilead, and Abbvie. M. Alvarez-Tejado, J. Gregori, and J. M. Muñoz work in Roche Diagnostic